Agendia is a leader in the precision medicine era, bringing more effective, individualized treatment within reach of breast cancer patients. Leveraging the latest advancements in cancer research, Agendia’s suite of tests are designed to help physicians more accurately individualize and optimize cancer therapy.
MammaPrint is the first and only genomic assay to attain Level 1A Clinical Utility Evidence for chemotherapy benefit in early-stage breast cancer patients.
MammaPrint helps you answer the most important clinical questions for the care and management of breast cancer patients:
Who is at risk for recurrence?
Which patients can safely forego chemotherapy?
What is the optimal treatment for each patient?
What is the risk of recurrence within 20 years?